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Despite a trend towards decreasing mortality, cardiovascular
disease (CVD) remains the major cause of death in the western
world [1,2]. Improved management of acute myocardial infarc-
tion (MI), earlier diagnostic procedures, and advanced interven-
tion techniques have resulted in an increasing number of CVD
survivors. Early rehabilitation and risk-factor management for
these individuals is essential to regain function and reduce the
risk of a second adverse cardiac event.
The use of exercise therapy in post-MI survivors began
gaining momentum in the late 1970s when it became clear
that immobilization and reduced activity, which was standard
therapy at that time, resulted in poor long-term prognosis and
survival [3]. Over the past 30 years, exercise therapy has
evolved into the multifactorial programs we know today as
CR. These programs, which include nutrition counselling,
smoking cessation, weight management, psychosocial coun-
selling and metabolic risk-factor management, can be found
in many hospitals and communities. The target population for
CR has expanded, and includes men and women of all ages
and those presenting with nonischemic CVD (Table 1).
Several national organizations have published extensive
recommendations and guidelines for CR [4–6].
The World Health Organization has defined CR as: “… the
sum of activity required to ensure cardiac patients the best
possible physical, mental and social conditions so that they
may, by their own effort, regain as normal a place in the com-
munity, and lead an active life” [7].
The goals of CR are restoration of optimal physiological,
psychological and vocational status, and reduction of risk of
cardiac morbidity and mortality.
As CVD is a multifactorial disease, the beneficial outcomes
from CR are numerous. Possible outcomes include improve-
ment in lifestyle, CVD risk-factors, cost of care, disease pro-
gression, morbidity, and mortality. To date, no single study
has conclusively demonstrated a comprehensive benefit of
CR. However, such a study is unlikely to ever be conducted,
as it would be unethical to assign individuals with CVD to a
non-CR control group. Instead, the data from various studies,
each investigating one or two outcomes, must be compiled to
identify the overall benefit of CR.
The present review will trace the evidence from studies on
exercise therapy in post-MI survivors to the comprehensive
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Abstract
Cardiac rehabilitation (CR) is a commonly used treatment for men and women with cardiovascular
disease. To date, no single study has conclusively demonstrated a comprehensive benefit of CR.
Numerous individual studies, however, have demonstrated beneficial effects such as improved risk-
factor profile, slower disease progression, decreased morbidity, and decreased mortality. This paper will
review the evidence for the use of CR and discuss the implications and limitations of these studies. The
safety, relevance to special populations, challenges, and future directions of CR will also be reviewed.
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programs we know today. Excellent reviews of dietary and
smoking interventions have been written, and the reader is
directed to these [8,9]. At the end of this review, evidence in
other populations will be discussed, as well as the challenges
facing CR programs today and areas requiring further study.
The modern CR program
Figure 1 outlines the multidisciplinary nature of the modern
CR program. CR comprises three distinct phases: inpatient,
outpatient, and in the community/home. Participation in these
programs is determined by appropriate risk stratification to
maximize health care resources and benefits. The inpatient
program consists of low-level activities that gradually
progress throughout the hospital stay to prevent recondition-
ing. Education and counselling also begin at this time. The
outpatient program is the most common CR model in use and
may last from 2 to 4 months. These programs combine physi-
cian-supervised exercise sessions with cardiovascular risk
reduction, commonly using a case management model. A full
risk-factor and lifestyle assessment is conducted both at the
beginning and end of the program. On completion of the out-
patient program, patients can then continue in a local commu-
nity center CR program. Patients who are at low risk may
appropriately continue their program in a home-based setting.
Evidence for the benefits of CR
Mortality trials
The benefits of physical activity and exercise have been rec-
ognized for centuries. Numerous epidemiological studies
have associated physical activity participation with reduced
CVD risk and mortality [10–12]. Based on this association,
early investigations set out to determine the survival benefits
of exercise therapy and CR. These studies were mainly
restricted to middle-aged men who had experienced a prior
MI. Interventions lasted from 6 weeks to 3 years and con-
sisted of mainly exercise therapy, while a few included other
lifestyle strategies (dietary, smoking cessation and psycho-
social counselling). The results of these studies have varied.
Some have reported nonsignificant changes in mortality
[13–17], while others have demonstrated significant reduc-
tions in mortality [18–21]. Sample sizes in these studies
varied from 167 to 651 participants, much smaller than other
mortality trials, which may account for some of the nonsignifi-
cant findings. Differences in the intervention method, the
duration, and the follow-up period also confound compar-
isons between studies.
Much of the evidence to support reduced mortality from CR is
provided by two meta-analyses that have been conducted to
combine the results of the earlier exercise therapy and CR
studies [13–18]. These investigations were restricted to studies
of men and women post-MI. Oldridge et al included data from
20 studies totalling 4347 patients (2202, intervention; 2145,
control) [22], while O’Connor et al included 22 studies totalling
4554 patients (2310, intervention; 2244, control) [23]. All-
cause and cardiovascular mortality in the exercise therapy group
were significantly reduced compared with the control group
(Table 2). No significant difference in nonfatal MI was reported
in either analysis; in fact, slightly more occurrences were noted
in the intervention group. The authors speculated that those par-
ticipants in the exercise therapy group were more likely to
Table 1
Target populations for participation in cardiac rehabilitation
programs
Ischemic heart disease
Post-MI, coronary artery bypass graft, percutaneous 
transluminal coronary angioplasty
Stable angina
Other heart conditions
Compensated heart failure
Controlled dysrhythmias
Automatic implanted cardioverter-defibrillate/pacemaker
Post-valve replacement
Cardiomyopathy
Myocardial aneurysm resection
Pre- and post-heart transplant
Congenital heart defects
Other chromic diseases
Stroke
Peripheral vascular disease
High risk of developing CVD
CVD, Cardiovascular disease; MI, myocardial infarction.
Figure 1
Diagrammatic outline of the modern cardiac rehabilitation program.
ECG, Electrocardiography.
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survive a repeat MI than those in the control group. The similar
finding between these two meta-analyses is not surprising since
16 of the studies analyzed were common to both; the results
should therefore not be considered independent of one another.
Because women accounted for less than 3% of the patients,
gender-related outcomes were not analyzed. The relative reduc-
tion of all-cause and cardiovascular mortality (approximately
20–25%) is similar to the reduction in mortality observed in
lipid-lowering trials [24].
Since these two meta-analyses were completed, four other
studies have been published reporting outcomes from 2 to
19 years of follow-up (summarized in Table 3) [20,21,25,26].
Three of these studies reported results of earlier follow-up
periods that were incorporated into the previous meta-analy-
ses [14,18,27], while the fourth had not been previously
reported [20].
First, the PRECOR group randomized men to either a 6-week
CR, a counselling program, or control (usual care, no inter-
vention) [20]. No difference in all-cause mortality was
observed between the three groups after 2 years follow-up
but, when the counselling program and control groups were
combined and compared with the CR group, a significant dif-
ference did exist in favor of CR.
In the second study, Hedback and Perk found no difference in
all-cause or cardiovascular mortality after 5 years of follow-up
between the non-randomized CR and reference groups [27].
At 10 years, significant reductions were observed in these out-
comes as well as in sudden death and nonfatal MI [21].
Hamalainen et al randomized 375 participants to either a multi-
factorial CR intervention or control (usual care, no intervention
for 10 years [19]. The authors reported significant reductions in
sudden death and cardiovascular mortality, with no difference
Available online http://cvm.controlled-trials.com/content/2/5/221
Table 2
Summary of major findings from two meta-analyses of
randomized exercise therapy and cardiac rehabilitation trials
Oldridge O’Connor 
et al [22] et al [23]
All-cause mortality 0.76 (0.63–0.92)* 0.80 (0.66–0.96)‡
Cardiovascular mortality 0.75 (0.62–0.93)† 0.78 (0.63–0.96)‡
Sudden death Not reported 0.92 (0.69–1.23)
Nonfatal myocardial infarction 1.15 (0.93–1.42) 1.09 (0.88–1.34)
Data presented as odds ratio (95% confidence intervals). Values
below 1.00 favor cardiac rehabilitation intervention. * P = 0.004, 
† P = 0.006; ‡ significantly lower than comparison group, no P values
reported.
Table 3
Summary of recent randomized exercise therapy and cardiac rehabilitation (CR) trials investigating the effects on long-term
mortality
Follow-up
Cohort Intervention Comparison group (years) Relative risk reduction*
Hedback 305 men and women, Multifactorial, 2 x per week Non-randomized reference 10 27% all-cause mortality 
et al [21] post-MI, < 65 years exercise sessions, 3 months with no CR (P < 0.01)
24% cardiovascular mortality 
(P < 0.001)
33% nonfatal MI (P < 0.001)
PRECOR 182 men post-MI, Multifactorial, 3 x per week Control (usual care, 2 7% absolute reduction in 
Group [20] < 65 years exercise sessions; or no intervention) all-cause mortality† (P = 0.08)
counselling only, 6 weeks
Hamalainen 375 men and women, Multifactorial, exercise Randomized control group 15 4% all-cause mortality 
et al [25] post-MI, < 65 years sessions, 3 years (not significant)
18% cardiovascular mortality 
P = 0.04)
43% sudden death 
(P = 0.006)
NEHDP [26] 651 men, post-MI, Exercise only, 2 years Control (usual care, 19 No reported benefits
< 65 years no intervention)
MI, Myocardial infarction; NEHDP, The National Exercise and Heart Disease Project. * Relative risk reduction in favor of intervention. † No deaths
occurred in CR intervention. results are based on comparison of CR intervention with counselling intervention and control (usual care, no
intervention) combined.
in all-cause mortality or nonfatal MI. After 15 years of follow-up,
these reductions in the intervention group persisted for sudden
death and cardiovascular mortality [25].
Finally, the National Exercise and Heart Disease Project had
the longest follow-up period to date (19 years), yet failed to
demonstrate any reduction comparing exercise therapy with
control (usual care, no intervention), in all-cause or cardiovas-
cular mortality, with no report on nonfatal MI [26]. This result
was consistent during the five follow-up periods from 3 to
19 years. It is possible that the duration of the exercise-only
intervention, 8 weeks, was not long enough to produce
lasting benefits and therefore not as effective as the interven-
tions of the other studies.
Despite the lack of a consistent reduction in mortality and the
myriad of differences in these studies, there is a trend
towards reduced all-cause and cardiovascular mortality.
Owing to the study populations being overwhelmingly limited
to men younger than 65 years post-MI, investigation of
gender-related results was not possible. The possible benefit
of CR in older adults and in those who have CVD but have
not experienced a previous MI is also unclear.
Comprehensive disease regression trials
More recent CR trials have focused on other clinical out-
comes such as atherosclerotic progression (summarized in
Table 4). This is due to the high correlation between
disease progression and cardiac events [28]. The use of
disease progression as an outcome allows for a smaller
sample size and follow-up period than required by a mortal-
ity trial.
Schuler at al studied a group of 36 men with stable angina
and coronary artery stenosis, and assigned them to either
CR (dietary counselling, twice-weekly exercise sessions, and
a home exercise program) intervention or to control (usual
care, no intervention) for 12 months based on proximity to
the study site [29]. Participants were asked not to use lipid-
lowering medications for the duration of the study. When
participants were grouped according to progression — no
change or regression of stenosis — the intervention group
underwent significantly less progression than the control
group. The authors also noted significantly improved myocar-
dial perfusion during maximal stress testing and decreased
total cholesterol in the intervention group.
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Table 4
Summary of comprehensive cardiac rehabilitation trials that used coronary atherosclerotic disease progression as the primary
outcome
Results
Study Follow-up duration Control Intervention P*
Schuler et al [29]† 1 year (n = 36) 33% progression, 28% progression, < 0.05
61% no change, 33% no change, 
6% regression 39% regression
Niebauer et al [30]† 5 years (n = 25) 75% progression, 38% progression, ns
13% no change, 38% no change, 
13% regression 25% regression
Schuler et al [31]† 1 year (n = 113) 48% progression, 23% progression, < 0.05
35% no change, 45% no change, 
17% regression 33% regression
Niebauer et al [33]† 6 years 74% progression, 59% progression, < 0.0001
26% no change, 22% no change, 
0% regression 19% regression
The Lifestyle Heart Trial [34,35]‡ 1 year (n = 41) 2.28 (–3.00 to 4.86) (n = 15) –1.75 (–4.08 to 0.58) (n = 18) 0.02
(53% progression, 18% progression, 
5% no change, (0% no change, 
42% regression) 82% regression)
5 years (n = 35) 11.77 (3.40–20.14) (n = 15) –3.07 (–5.91 to –0.24) (n = 20) 0.001
SCRIP [36]§ 4 years (n = 246) –0.045 ± 0.073 –0.024 ± 0.067 0.02
(50% progression, (50% progression, 
20% no change, 18% no change, 
10% regression, 20% regression, 
21% mixed changes) 12% mixed changes)
* Between-group comparisons; ns, not significant. † Progression, ≥ 10% decrease; no change, ≤ 10% change; regression, ≥ 10% increase in
percent minimal diameter. Patient assigned an average score when multiple stenoses analyzed. ‡ Average percent diameter stenosis change from
baseline; 186 lesions analyzed (77 control, 109 intervention) by quantitative coronary angiography. Results reported from participants completing a
5-year follow-up. § Absolute change in minimal diameter stenosis (mm) per year as assessed by quantitative coronary angiography.
This cohort was again followed-up 4 years later, at which time
the significant differences in disease progression between
groups no longer existed [30]. An increase in weight and total
cholesterol between years 1 and 5, possibly the result of
decreased dietary adherence, may have attenuated the differ-
ences in disease progression between groups.
Limitations of the previous study (small sample size, group
assignment of convenience) led the authors to conduct a
second study in 113 men with coronary artery stenosis [31].
The intervention was identical to the previous study but par-
ticipants were randomly assigned to either intervention or
control (usual care, no intervention). Participants in the inter-
vention group underwent significantly greater reductions in
dietary fat and total cholesterol, and a significantly greater
increase in maximal oxygen consumption, compared with the
control group. This resulted in a more favorable lipid profile,
and reduced weight, compared with control. Significantly
fewer participants in the intervention group experienced
disease progression compared with the control group at
1 year (23% versus 48%, respectively; P < 0.05). Further
investigation of this cohort did not determine any difference in
coronary collateral formation between groups [32].
Five years later, there was still a significant difference
between the intervention and control groups with respect to
disease progression (59% versus 74%, respectively;
P < 0.05) [33]. This difference was significant for ‘per lesion’
and ‘per patient’ comparisons. No significant differences
existed in clinical events, and the significant differences in
lipid profile and weight that occurred at 12 months were no
longer evident at 6 years. The authors reported a significant
correlation between exercise capacity and relative stenosis
diameter (r = 0.319, P < 0.01). In contrast to the previous
study, the exercise capacity of the intervention participants
continued to improve between years 1 and 6.
Two controlled studies that demonstrated the benefits of
comprehensive CR are (Table 4) the Lifestyle Heart Trial
(LHT) [34,35] and the Stanford Coronary Risk Intervention
Project (SCRIP) [36]. Both of these studies included men
and women with documented coronary artery disease, and
used disease progression (assessed by quantitative coronary
angiography) as the outcome.
The LHT
The unique approach of the LHT was to demonstrate the
effectiveness of aggressive lifestyle management, with no
lipid-lowering medications, to induce disease regression. Eli-
gible men and women were identified from their hospital
charts and randomly assigned either to the intervention or
control (usual care, no intervention) without prior consent.
These individuals were then contacted by the study co-
ordinator, informed of their group assignment and asked to
provide informed consent. Of the 93 individuals contacted,
only 48 (five women) agreed to participate. The intervention
consisted of an initial 1-week retreat, a low-fat vegetarian diet,
twice-weekly group support meetings, stress management,
and monitored weekly exercise.
Adherence to the intervention was reported to be high. After
1 year, significant reductions in weight and lipid values were
noted in the intervention group. All detectable lesions were
included in the final analysis. With respect to percent diame-
ter stenosis, disease regression occurred in the intervention
group while the control group experienced disease progres-
sion. This difference was significant, even when lesions less
than 50% stenosed were excluded. The authors also noted a
dose-dependent relationship between program adherence
and change in percent diameter stenosis.
After 5 years, adherence to the program decreased modestly
for the intervention participants [35]. There was also a
modest deterioration of lipid values between years 1 and 5 in
the intervention group and participants gained back one-half
of the weight lost in the first year. Despite this, participants in
the intervention group continued to undergo further disease
regression (7.9% relative regression) while the control group
underwent disease progression (27.7% relative progression).
The authors again noted a dose-dependent relationship
between program adherence and change in percent diameter
stenosis. Participants in the control group experienced nearly
double the amount of cumulative combined cardiovascular
events than in the intervention group (2.25 versus 0.89
events per patient).
This study identified the importance of lifestyle modification
for the treatment of CVD and demonstrated its feasibility in a
self-selected population. However, incorporation of this
program into daily practice may prove difficult because it
requires a great deal of resources per patient and highly moti-
vated individuals; over 50% of those participants randomized
to the intervention program refused participation and were
not followed on an intent to treat basis.
SCRIP
The SCRIP continues to be one of the largest, randomized,
long-term multifactorial CR studies to date [36]. The interven-
tion used in this study is markedly different from that of previ-
ous studies; participants randomized to the intervention
underwent counselling sessions by a nurse and a dietician
every 2–3 months only, and no on-site exercise sessions
were conducted. During the counselling sessions, partici-
pants were prescribed a home exercise program, prescribed
lipid-lowering medications, and underwent a smoking cessa-
tion program as required. Unlike previous studies, the SCRIP
did not include an on-site exercise program; however, exer-
cise capacity increased significantly in the intervention group
compared with in the control (usual care, no intervention)
group (1.7 ± 2.4 versus 0.7 ± 2.1 metabolic equivalents
[METs] above baseline values, respectively; P = 0.001). The
inclusion of lipid-lowering medications is also a departure
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from the other studies, but this reflects changes in clinical
practice and the use of all clinical tools at the disposal of the
CR program.
After 4 years, lipids, systolic blood pressure, body composi-
tion, and fasting glucose all significantly improved in the inter-
vention group compared with the control group. There was
no change in the proportion of smokers after 4 years. Partici-
pants in the intervention group underwent significantly less
absolute change in the minimal, and mean, diameter of dis-
eased vessels compared with the control group. This was
significant for both ‘per patient’ and ‘per vessel’ analyses, and
remained significant after adjusting for age and baseline
segment diameter.
Although not an a priori endpoint, the intervention group
experienced significantly fewer cardiac events compared to
participants in the control group (n = 44 versus n = 25,
respectively; P = 0.05). This finding is similar to that of the
LHT. The majority of the events experienced by the interven-
tion group occurred during the study’s first year, which were
mostly percutaneous transluminal coronary angioplasty
(PTCA) procedures. The authors speculated that the
increased contact with the intervention staff might have
uncovered the need for these patients to undergo the proce-
dure at an earlier stage.
This study is unique in that it used a physician-supervised,
nurse-managed intervention, a method that is easily replicable
in other clinics and does not require on-site exercise ses-
sions. However, the SCRIP intervention used risk-factor
targets to guide treatment strategies, which were considered
to be aggressive at the time and beyond current guidelines.
This may have resulted in a bias towards success for the
intervention group.
These studies have demonstrated that CR with or without
lipid-lowering medication use is effective at reducing disease
progression. The reduction of progression observed in the
SCRIP is equivalent or superior to a number of trials investi-
gating the effects of lipid-lowering only [28,37,38], and
reflects the benefit of multifactorial CR interventions utilizing
all clinical tools. The mean regression demonstrated in the
LHT by lifestyle changes alone has not been realized in most
pharmacological interventions. In spite of the small sample
size and self-selected population in the LHT, these results are
impressive. The reduction in events reported in the LHT and
the SCRIP attests to the benefit of disease regression by CR.
Risk-factor modification
CR studies investigating clinically relevant endpoints have
been limited to those previously discussed. As with other
CVD interventions, CR is aimed at modifying various CVD
risk-factors based on the evidence that risk-factor reduction
will reduce morbidity and mortality. The SCRIP demonstrated
that CR is effective at comprehensive risk-factor modification,
resulting in reduced disease progression and clinical events.
Table 5 summarizes the strength of evidence for the use of
CR for CVD risk-factor modification and quality of life
improvements.
The case management model
With the growing number of CVD survivors, traditional exer-
cise-based CR programs will not have the resources to meet
the demand for their services. Exercise-based programs may
not be necessary for patients at low and moderate risk. The
SCRIP demonstrated that CR could be effective without a
supervised exercise component. The SCRIP and other
studies have led to the development of the nurse case man-
agement system.
The Multi-Fit model is a physician-supervised, nurse-managed
intervention. DeBusk et al studied this model in 585 patients
(20% women) who were recruited while recovering in hospi-
tal from a recent MI [39]. Participants were randomized to
either an intervention or a control group. The intervention was
based on social learning theory, which consisted of goal
setting for lifestyle behaviours based on the participants'
motivation to change, identification of possible barriers to
change and relapse prevention strategies. The intervention
began with lifestyle counselling during the hospital stay. Fol-
lowing discharge, contact with intervention participants was
restricted to telephone and mail, with a maximum of four visits
with the nurse during the 12-month intervention. The interven-
tion focused on smoking cessation, diet, exercise, and lipid-
lowering therapy (limited to bile acid resins and niacin).
Exercise capacity was greater at 6 months in the intervention
group than in the control (usual care, no intervention) group
(9.3 and 8.4 METs, respectively). No report on exercise
capacity was provided at 12 months. At the end of
12 months, smoking cessation rates (70% versus 53%,
P = 0.03), total cholesterol (–0.64 mmol/l versus
–0.09 mmol/l, P < 0.001) and low-density lipoprotein choles-
terol (–0.65 mmol/l versus –0.14 mmol/l, P < 0.001) reduc-
tions were significantly greater in the intervention group than
in the control group.
This novel intervention strategy demonstrates effective risk-
factor management without requiring numerous patient visits.
The use of telephone and mail contact greatly reduced the
nurse intervention time (average 9 hours per patient), and
allowed for a greater number of participants (nearly double) in
the intervention than any other study.
As the study was only conducted for 1 year, it does not
provide additional information on clinical outcomes. However,
the 24% relative reduction of low-density lipoprotein choles-
terol is similar to that observed in long-term lipid-lowering
trials that demonstrated significant reductions in mortality
[40]. The authors of this intervention have already reported on
the benefits of its use in clinical practice [41].
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Safety of CR
The use of exercise therapy for patients with CVD has proven
effective, but also carries a burden of risk. Physical exertion
has been reported to be a trigger of MI and sudden cardiac
death in individuals both without known CVD [42,43] and
with CVD [44–46]. Previous documentation of CVD did not
appear to increase the risk of MI during exercise [44,45].
Mittleman et al reported an increased risk of 5.9 times for MI
during physical exertion in 1228 men and women. When
stratified by activity levels, this risk was reduced to 2.4 for
individuals who were ‘active’ more than five times per week,
and increased to a remarkable 107 for sedentary individuals
[44]. Other studies have similarly reported a reduced risk of
MI during exercise in the habitually active compared with
sedentary individuals [43,45]. The issue of complications
during CR has been reported in several studies [36,47–49].
These studies report complication rates from 1.23 to 2.88
and fatalities from 0.13 to 0.86 per 100,000 patient-hours.
There is a trend towards less frequent events reported in the
more recent studies, suggesting that current CR programs
may be safer than the earlier ones. Electrocardiographic
telemetry is widely used in CR programs as a safety precau-
tion; however, its use has not been demonstrated to be
superior to traditional CR supervision [47,48].
CR for congestive heart failure
Coincident with the increased number of survivors of CVD is
the increase in individuals suffering from congestive heart
failure (CHF). It is predicted that CHF will become the cardio-
vascular epidemic of the future [1]. Two randomized studies
have demonstrated the benefits of exercise therapy [50,51].
In one study, 73 men were randomized to an intervention of
daily-prescribed home exercise or to control (usual care, no
intervention) [50]. After 6 months, the intervention group had
significant improvement in exercise capacity, New York Heart
Association functional class, maximal ventilation, mean total
peripheral resistance, and stroke volume. Left ventricular
ejection fraction (LVEF) improved from 30 ± 8% at baseline
to 35 ± 9% at 6 months.
The second study randomized 99 men and women with CHF
to a supervised intervention of twice-weekly exercise
sessions or to control (usual care, no intervention) for
14 months [51]. Exercise capacity increased from baseline to
14 months to a greater extent in the intervention group
(15.7 ± 2 ml/kg/min to 19.9 ± 1 ml/kg/min) compared with
the control group (15.2 ± 2 ml/kg/min to 16 ± 2 ml/kg/min,
P < 0.001). Much of the increase in exercise capacity in the
intervention group occurred during the initial 2 months.
Quality of life also increased significantly in the intervention
group as measured by the Minnesota Living with Heart
Failure Questionnaire. However, no changes were reported in
the control group. In contrast to the previous study, LVEF did
not change significantly in the intervention group. Despite
this, a significant difference in combined cardiac events (17
versus 37, P = 0.006), CHF readmission (5 versus 14,
P = 0.02), and cardiac mortality (9 versus 20, P = 0.01) was
observed between groups at 14 months. These studies
provide definite support for the inclusion of CHF patients in
CR programs.
Efficacy in other populations
The majority of CR studies to date have been restricted to
middle-aged men who suffered a recent MI, yet patients
enrolled in CR programs comprise a much broader popula-
tion. Only recently have these populations been included in
CR studies and, as a result, outcome data is limited.
Several of the more recent studies have included women, but
these numbers have been too small to separately determine
morbidity and mortality rates. Women have traditionally had
lower rates of CVD than men but it is anticipated that this dis-
crepancy will decrease in the future [2]. The limited number
of CR studies investigating women has found significant risk-
factor modification, similar to that observed in men [52,53].
Individuals older than 65 years are also often excluded from
studies. When compared with younger adults, elderly individ-
uals demonstrate similar benefits to CVD risk-factors, and
exercise capacity [53–55].
A growing population of CR participants has undergone a
prior revascularization procedure without experiencing a pre-
vious MI. Evidence suggests that patients who have under-
gone PTCA have different perceptions of their own health
and their need for risk-factor reduction [56,57]. However,
these patients can benefit from CR participation [58].
Available online http://cvm.controlled-trials.com/content/2/5/221
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Table 5
Strength of evidence ratings for modification of various
outcomes and cardiovascular disease risk-factors as a result of
cardiac rehabilitation participation
Strength of Highlighted
Outcome evidence* references
Smoking cessation, relapse prevention B [39,79]
Improved lipid profile A [31,36]
Decreased blood pressure B [19]
Improved blood sugar control B [80]
Increased exercise capacity A [81,82]
Increased physical activity B [83]
Decreased body weight B [36]
Improved psychosocial well-being A [84,85]
Improved social functioning B [86]
* A, Evidence provided by well-designed, controlled trials with
statistically significant results consistent across trials; B, evidence
provided by observational studies or controlled trials with less
consistent results; C, opinion of expert consensus due to a lack of
controlled trials and/or consistent results.
Patients who have undergone previous coronary artery
bypass graft can also effectively reduce their risk-factors as a
result of CR [59].
Other groups that participate in CR programs include those
with post-heart transplantation, or those with atrial fibrillation
and valve disorders. One randomized trial has been con-
ducted investigating the benefits of exercise therapy following
heart transplantation. Twenty-seven men and women were
assigned to either a 6-month supervised exercise intervention
or to control (usual care, no intervention) which included
written instructions for exercise [60]. Both groups showed
improved exercise capacity, but the intervention group
improved to a greater extent than the control group (from
9.2 ml/kg/min to 13.6 ml/kg/min versus from 10.4 ml/kg/min
to 12.3 ml/kg/min, respectively; P = 0.01).
Much less information has been reported on patients with
atrial fibrillation and valve disorders. Those studies that do
exist suggest these populations can benefit from participation
in CR [61,62].
Challenges of CR
Despite the numerous benefits of CR, several challenges
exist that are common to most programs. These challenges
include low participation rates, gender-biased referral and
participation, problems with adherence/drop-outs, and
resource management (Fig. 2). Participation rates in CR pro-
grams by those patients who are eligible are disappointing,
ranging from 8.7% to nearly 50% [63–66]. Possible reasons
for low participation include lack of referral, distance to CR
facility (current CR programs are commonly restricted to
urban centers), lack of motivation, and patient’s unwillingness
to attend.
Demographic predictors of attendance were younger age,
male gender, employment, and education. Women who do
attend CR programs have been found to present at a higher
CVD risk than men [67]. This is consistent with reported
gender discrepancies for other CVD interventions [68]. It is
possible that referral rates are lower for women than men;
however, it has also been reported that women are more
likely to drop out of a CR program once referred [69].
The benefits of CVD risk reduction are only realized through
long-term lifestyle, and risk-factor management. CR drop-outs
and adherence continue to pose a challenge to the success of
CR. In many of the studies described, drop-outs were directly
related to the intervention. These drop-out rates tend to be
higher than those reported in controlled pharmacological inter-
vention trials [70]. A number of articles have described the
problem of CR drop-outs [71–73]. Even after CR participa-
tion, adherence rates to favorable lifestyle behaviors have
been reported to decline [74,75]. However, good comprehen-
sive data on adherence following completion of CR and its
influence on risk-factor modification have not been reported.
To this end, the present authors have completed a pilot study
of CR graduates. Six months following CR, adherence to
exercise and diet remained high, and the risk-factor benefits
of the CR program persisted [76]. Similar results were
observed 6 months after completing CR in a study of 15 indi-
viduals [77].
Only one other study has reported CVD risk-factor trends fol-
lowing completion of CR. Willich et al described risk-factor
changes 12 months following CR [78]. In the 2441 patients
followed, risk-factors significantly improved as a result of the
CR program, but these changes were later attenuated at
12 months.
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Figure 2
Current challenges faced by today’s cardiac rehabilitation programs
and recommended future directions of study. CHF, Congestive heart
failure.
Longer studies are currently in progress. As a follow-up to our
pilot study, the authors are currently following 302 CR gradu-
ates in the Extensive Lifestyle Management Intervention Trial.
Participants have been randomized to a modest intervention
or control, and have been followed for 4 years. The results of
this study will provide comprehensive lifestyle and risk-factor
trends following CR, and the effect of a follow-up intervention
on these factors.
Coincident with the challenge of adherence is that of
resource management in light of the predicted increase in eli-
gible participants. As the eligible population for CR services
grows, CR programs will need to treat more patients without
similar increases in health care resources. The Multi-Fit study
demonstrated that significant risk-factor modification could
occur with limited contact between patient and health care
provider [39]. Whether these benefits can persist beyond
1 year is unknown.
Future directions of CR
As CR has evolved in the past 30 years, it has proven its
value in the treatment of patients following MI. In the coming
years, the challenges will be no less demanding (Fig. 2). As
new target patient populations are recruited into CR pro-
grams, the safety and efficacy of CR in these populations
needs to be established, particularly in those with CHF, atrial
fibrillation, and valvular disease. Strategies for improving par-
ticipation rates need to be developed, focusing on education
of patients and health care providers. Extra efforts should be
directed towards reducing the gender inequity. The possibility
of disease regression needs to be explored in larger popula-
tions using clinically relevant practices.
Our program is currently evaluating atherosclerotic regres-
sion through aggressive lifestyle and risk-factor management
in a group of 150 men and women over a 2-year period using
carotid artery intima–media thickness as an outcome.
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Figure 3
Proposed organizational structure for new cardiac rehabilitation (CR) models. ECG, Electrocardiography.
New models of CR need to be developed and studied for
both safety and efficacy — preferably in randomized trials
compared with standard CR programs. These new CR pro-
grams will need to address issues of promoting long-term
adherence, improving accessibility, particularly for patients in
suburban and rural communities, and addressing the growing
need for CR in an ageing population. Future CR programs
will also need to be resource sparing, as current health care
organizations cannot meet the demand of all eligible patients.
These new models will need to maximize delivery of
resources to those who require them. For those patients
living in rural areas, new communication technologies may
prove useful in delivering CR through telemedicine initiatives.
Appropriate risk stratification will aid in health care resource
management, restricting outpatient CR programs to those
patients at high risk and utilizing less frequent contact for low
and moderate risk patients. Greater reliance on existing com-
munity resources will be required, allowing low and moderate
risk patients to exercise at community centers or at home
while remaining in contact with the outpatient CR center.
Integration with patients’ family physicians and other health
care providers, such as the pharmacist, is a potential strategy
to improve adherence, as are behavior strategies aimed at
patient empowerment. Other forms of contact than the tradi-
tional face-to-face session can be incorporated into CR as a
method of continued follow-up and reaching those patients in
non-urban areas. The growth of telemedicine can play a vital
role; from the simple use of the telephone, to the Internet, to
the use of personal digital assistants. Integration of these and
other tools can address a number of the issues of CR (Fig. 3).
Conclusion
The numerous studies investigating exercise therapy and CR
have each demonstrated some beneficial effect, whether it is
an improved CVD risk-factor profile, slower disease
progression, reduced morbidity, or mortality. Owing to the
multifactorial nature of CVD and the design of these studies,
it is difficult to extrapolate any one study to the CVD popula-
tion at large. Some studies have also used interventions that
have limited relevance to day-to-day clinical practice. Aggres-
sive lifestyle/CVD risk-factor management and multi-year
interventions are not practical for most health care settings.
Limitations of current CR research include the lack of large
randomized trials and inconsistent interventions (duration and
methodology) that have not been previously validated. This is
due in part to the heterogeneity of the CVD population, the
numerous resources required to effectively conduct a CR
intervention, and the difficulty with blinding participants and
investigators.
In spite of some limitations, the accumulative evidence
strongly supports the use of exercise therapy and CR for the
treatment of men and women with ischemic heart disease.
Through effective lifestyle and CVD risk-factor management,
CR has been demonstrated to lead to slow disease progres-
sion, and even regression in some individuals, resulting in a
decrease in cardiovascular morbidity, and mortality. Despite
several studies restricting the use of lipid-lowering medica-
tions (demonstrating the efficacy of the lifestyle interventions),
it is important for the CR health care professional to make
use of all treatment tools at their disposal. Comprehensive
CR programs should integrate lifestyle and pharmacological
treatment as appropriate. A limited number of studies have
shown CR to be beneficial in other cardiovascular popula-
tions, and it is recommended that these individuals be
included in CR programs. Future research should be directed
at characterizing the full benefits in other populations as well
as investigating new models of CR delivery to meet the
anticipated increase in eligible participants.
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